Making Success More Certain
We partner with innovative and leading pharmaceutical companies to enable the development, manufacturing, and packaging of small and large molecule drug products.
We help drive your drug programs to market success
- At Bora Pharmaceuticals, we see it as our mission, our duty, our responsibility, to make our success and our customer’s success more certain.
Bora Pharmaceuticals is a premier international contract development and manufacturing organization (CDMO) specializing in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, semi-solid, biologics, and sterile injectable pharmaceutical products.
From our world-class sites in North America and Asia, we deliver drug products with unparalleled quality to more than 100 markets around the world. Bora’s teams, technologies, and facilities work seamlessly together to enable our clients to deliver much-needed therapeutics to patients worldwide.
Manufacturing sites
We supply drugs to over 100 countries around the world
Manufacturing space
globally across our sites in North America and Asia
Years of experience
in development, manufacturing and packaging of Rx and OTC medicine
Markets
in personnel, equipment, and facilities over the past 10 years
Diverse small molecule drug product manufacturing and packaging capabilities
- Leverage Bora’s premium contract manufacturing offerings for oral solid doses (OSD), semi-solids, liquids, nasal sprays, and ophthalmics using state-of-the-art technologies to get your prescription (Rx) and OTC medicines reliably and faster to patients around the world.
Our global presence and reach
- With our global manufacturing sites and worldwide reach, we can meet your country-specific commercial and regulatory requirements with expertise and diligence.
Bora currently owns and operates nine state-of-the-art cGMP manufacturing facilities – in Taiwan, Canada, and the United States – built to the highest international standards for development, manufacturing, packaging, labeling, and analytical testing.
cGMP manufacture and supply of finished drug products to over 100 countries worldwide including countries in North, Central, and South America, Europe, Russia, the Middle East, Asia as well as Australia, and New Zealand.
Looking for a trusted partner to bring your breakthrough drug successfully to market?
Our team is here to discuss how you can gain competitive advantage by gearing Bora’s rich and diverse manufacturing and packaging expertise towards your commercial success.
Milestones
Our Journey to Becoming a Global Contender
2007
Bora Pharmaceuticals was founded by Bobby Sheng with a mission of “Contributing to Better Health All Over the World” and to become a world-leading pharmaceutical services company.
2013
Bora acquires Eisai Tainan Facility
2017
Bora completes IPO on Taipei Stock Exchange and acquires Yuta Health
2018
Bora enters US CDMO market with acquisition of Impax/Amneal’s USDA Zhunan Facility
2020
Bora acquires GSK Mississauga facility
2022
• Bora entered large molecule sector, acquired Eden Biologics and established Bora Biologics.
• Merged with Taiwan’s complex generics leader TWi.
2023
• Bora becomes major shareholder of SunWay Biotech.
• Bora listed on Taiwan Stock Exchange.
• Launched Dexlansoprazole DR in the U.S., named a top 2023 launch by IQVIA.
2024
Completed the acquisition of Upsher-Smith and a Maryland-based site (ex-Emergent) to drive business transformation, and made a strategic investment into Tanvex to provide global biomanufacturing services.
2025
Bora completed strategic investment into Tanvex, a Biosimilar company for CDMO endeavors.